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1. INTRODUCTION {#clc23185-sec-0006}
===============

Eicosapentaenoic acid (EPA) is a member of a group of n−3 polyunsaturated fatty acids derived from fish oil. Epidemiologic data suggest that long‐term intake of n−3 polyunsaturated fatty acids plays an important role in reducing adverse cardiovascular events.[1](#clc23185-bib-0001){ref-type="ref"} Moreover, some clinical studies suggested that administration of purified EPA for secondary and primary prevention lowers the total and ischemic cardiovascular mortality.[2](#clc23185-bib-0002){ref-type="ref"}, [3](#clc23185-bib-0003){ref-type="ref"} Optical coherence tomography (OCT) and optical frequency domain imaging (OFDI) are helpful intravascular imaging modalities that use the reflection of near‐infrared light to create images. Recently, many OCT and OFDI studies have reported the characteristics of unstable plaques, including plaque rupture,[4](#clc23185-bib-0004){ref-type="ref"}, [5](#clc23185-bib-0005){ref-type="ref"}, [6](#clc23185-bib-0006){ref-type="ref"} lipid‐rich plaques,[7](#clc23185-bib-0007){ref-type="ref"} thin‐cap fibroatheroma (TCFA),[8](#clc23185-bib-0008){ref-type="ref"}, [9](#clc23185-bib-0009){ref-type="ref"} cholesterol crystals,[10](#clc23185-bib-0010){ref-type="ref"}, [11](#clc23185-bib-0011){ref-type="ref"} macrophage accumulation,[12](#clc23185-bib-0012){ref-type="ref"}, [13](#clc23185-bib-0013){ref-type="ref"} and microchannels.[8](#clc23185-bib-0008){ref-type="ref"}, [14](#clc23185-bib-0014){ref-type="ref"} Several coronary computed tomography studies have shown that coronary plaques had lower plaque burden in patients receiving EPA therapy than in those not receiving EPA therapy.[15](#clc23185-bib-0015){ref-type="ref"}, [16](#clc23185-bib-0016){ref-type="ref"} Furthermore, intravascular ultrasound studies have indicated smaller coronary atherosclerotic plaque or lipid volume in patients on EPA therapy than in those not on EPA therapy.[17](#clc23185-bib-0017){ref-type="ref"}, [18](#clc23185-bib-0018){ref-type="ref"} However, no study has comprehensively examined whether EPA therapy is associated with decreased plaque instability in patients undergoing percutaneous coronary intervention (PCI) using OFDI. This study aimed to investigate the association between EPA therapy and coronary plaque instability in patients undergoing PCI using OFDI.

2. METHODS {#clc23185-sec-0007}
==========

2.1. Sample population and follow‐up {#clc23185-sec-0008}
------------------------------------

Data collected from 98 men and 23 women aged \>30 years who consecutively underwent OFDI‐guided PCI between October 2015 and July 2018 at Hokkaido Cardiovascular Hospital in Japan were retrospectively analyzed. A total of 109 untreated patients were allocated to the no‐EPA group, whereas 12 patients treated with EPA for ≥1 month were assigned to the EPA group. Patients presenting with left main coronary artery disease (CAD) and cardiogenic shock were excluded.

This study was approved by the ethics committee of Hokkaido Cardiovascular Hospital and was conducted in accordance with the ethical principles of the Declaration of Helsinki for medical research involving human subjects. The committee approved the image analysis, using only the data which were gotten when performing PCI.

2.2. Coronary angiography {#clc23185-sec-0009}
-------------------------

Coronary angiograms were analyzed by offline quantitative coronary angiography (GE ver. 5.10.1; Pie Medical Imaging BV, Maastricht, the Netherlands). Reference diameter, minimum lumen diameter, diameter stenosis, and lesion length were measured.

2.3. OFDI and analysis {#clc23185-sec-0010}
----------------------

An OFDI catheter (FastView; Terumo Corporation, Tokyo, Japan) was advanced using a 0.014‐in. guide wire with the help of a 6‐ or 7‐Fr guiding catheter, and the imaging core was placed at the distal site of the lesion. Images obtained using OFDI were obtained using a continuous flush of contrast media at a rate of 4 mL/s, and the OFDI wire was pulled back at a rate of 20 to 40 mm/s. Although OFDI was generally performed without dilation using a balloon catheter, the lesion was dilated using a small‐sized balloon if the OFDI catheter could not pass through the lesion because of severe stenosis. Aspiration thrombectomy was performed before OFDI for patients with acute coronary syndrome who did not show spontaneous recanalization. The plaque morphology of culprit lesions was studied. Following identification of the most stenotic lesion, 5‐mm proximal and distal lesions (total length: 10 mm) were examined. Cross‐sectional images were analyzed at every 1 mm for each OFDI parameter. OFDI analysis was performed by two independent investigators (Takao Konishi and R. K.) who were blinded to each patient\'s clinical course. In case of discordance between the investigators, a consensus reading was performed.

2.4. OFDI definitions {#clc23185-sec-0011}
---------------------

OFDI analysis indicated the presence of plaque rupture, plaque erosion, calcified nodule, lipid‐rich plaque, TCFA, macrophage accumulation, microvessels, cholesterol crystals, and calcification in the plaque. Plaque rupture was defined as the presence of fibrous cap discontinuity leading to a communication between the necrotic core and lumen (Figure [1](#clc23185-fig-0001){ref-type="fig"}A).[19](#clc23185-bib-0019){ref-type="ref"}, [20](#clc23185-bib-0020){ref-type="ref"} Plaque erosion was defined as a lesion with a thrombus but without fibrous cap disruption.[21](#clc23185-bib-0021){ref-type="ref"} Thrombus was defined as a well‐delineated, high‐signal mass attached to the luminal surface or floating within the lumen.[20](#clc23185-bib-0020){ref-type="ref"} Lipid‐rich plaques were defined as lesions with a lipid arc of more than 180° (Figure [1](#clc23185-fig-0001){ref-type="fig"}B).[20](#clc23185-bib-0020){ref-type="ref"} Lipid arc was measured within a lipid‐rich plaque, and the maximum value was recorded (Figure [1](#clc23185-fig-0001){ref-type="fig"}B). Lipid‐core length was defined as the length of lipid plaque and was measured in the longitudinal view. Lipid index was defined as the maximum lipid arc multiplied by the lipid‐core length.[22](#clc23185-bib-0022){ref-type="ref"} Cholesterol crystals were defined as thin, linear regions of high signal intensity within the lipid plaque, without backscattering.[20](#clc23185-bib-0020){ref-type="ref"} TCFA was defined as an atheroma with a fibrous cap thickness (FCT) \< 65 μm.[20](#clc23185-bib-0020){ref-type="ref"} FCT was defined as the minimum thickness of a signal‐rich layer from the coronary artery lumen to the inner border of the underlying lipid in the culprit lesion (Figure [1](#clc23185-fig-0001){ref-type="fig"}C).[20](#clc23185-bib-0020){ref-type="ref"} Macrophage accumulation was defined as increased signal intensity within the fibrous cap, accompanied by heterogeneous backward shadows (Figure [1](#clc23185-fig-0001){ref-type="fig"}D).[20](#clc23185-bib-0020){ref-type="ref"} Semiquantification of macrophage accumulation was performed as follows based on axial and circumferential distribution: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation in \<1 quadrant; grade 3, clustered accumulation in ≥1 quadrant and \< 3 quadrants; and grade 4, clustered accumulation in ≥3 quadrants (Supporting Information Figure S1).[23](#clc23185-bib-0023){ref-type="ref"} The possible range of macrophage score was 0‐40, which is a summation of grades 0‐4 across all 10 slices. Microchannels were defined as small vesicular or tubular structures with diameters of 50‐300 μm within the intima (Figure [1](#clc23185-fig-0001){ref-type="fig"}E).[20](#clc23185-bib-0020){ref-type="ref"} The number of microchannels was counted across all 10 slices at every 1 mm. Calcification was defined as well‐delineated, low‐backscattering heterogeneous regions (Figure [1](#clc23185-fig-0001){ref-type="fig"}F).[20](#clc23185-bib-0020){ref-type="ref"}

![Representative coronary artery plaque images for optical frequency domain imaging (OFDI) analyses. A, Plaque rupture (white arrow) with fibrous cap discontinuity, leading to a communication between the LC and the lumen. LC, lipid core. B, Measurement of lipid arc in a lipid‐rich plaque. Maximum lipid arc was measured within a lipid‐rich plaque (yellow lines). C, Measurement of fibrous cap thickness (FCT). Minimum FCT was measured thrice at the thinnest part, and the three measurements were subsequently averaged (white arrows). D, Macrophage accumulation was defined as increased signal intensity within the fibrous cap, accompanied by heterogeneous backward shadows (arrowheads). E, Microchannels (yellow arrows) were defined as small vesicular or tubular structures with diameters of 50 to 300 μm within the intima. F, Calcification was defined as well‐delineated, low‐backscattering heterogeneous regions](CLC-42-618-g001){#clc23185-fig-0001}

2.5. Statistical analysis {#clc23185-sec-0012}
-------------------------

Propensity score‐matched analysis was performed to compare the two groups.[24](#clc23185-bib-0024){ref-type="ref"} The propensity of being in the EPA group was estimated using a logistic regression model with the following covariates in our study database: age, sex, body mass index, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease (CKD), smoking, previous PCI or coronary artery bypass grafting, previous myocardial infarction, prior statin use, acute coronary syndrome, hemoglobin A1c level, low‐density lipoprotein (LDL) cholesterol concentration, triglyceride concentration, and high‐density lipoprotein (HDL) cholesterol concentration. Each patient in the EPA group was matched to four patients in the no‐EPA group (1:4 matching), as there were more patients who did not receive EPA therapy. Greedy nearest‐neighbor matching without replacement was used.

Continuous and categorical variables are reported as means ± standard deviations and as counts and percentages, respectively. The normality of distributions was assessed using the Kolmogorov‐Smirnov test. Between‐group differences were analyzed using Pearson\'s *χ* ^2^ test or Fisher\'s exact test for categorical variables and Student\'s *t*‐test or Mann‐Whitney *U* test for continuous variables, as appropriate. A *P* value \< 0.05 was considered to indicate statistical significance. Single and multiple logistic regression analyses were carried out to identify independent risk factors for coronary artery plaque characteristics assessed using OFDI. Risk factors that emerged with *P* values (Wald statistics) \<0.05 in the single variable analysis were entered in the multiple variable regression analysis. Data were analyzed using [spss]{.smallcaps} statistical software version 25.0 (IBM Corporation, Armonk, NY, USA).

3. RESULTS {#clc23185-sec-0013}
==========

3.1. Clinical characteristics {#clc23185-sec-0014}
-----------------------------

After the propensity score matching, OFDI images from 60 patients were analyzed in this study. The clinical characteristics of the two patient groups are compared in Table [1](#clc23185-tbl-0001){ref-type="table"}. Although EPA/arachidonic acid ratios were available only in 31 patients (10 in EPA group and 21 in no‐EPA group, the mean EPA/arachidonic acid ratio was significantly higher in the EPA group than in the no‐EPA group (1.63 ± 0.46 vs 0.48 ± 0.21, *P* \< 0.001). The mean LDL cholesterol concentration was 94 ± 29 mg/dL in the no‐EPA group and 97 ± 36 mg/dL in the EPA group (*P* = 0.807). Furthermore, the mean triglyceride concentration was 161 ± 92 mg/dL in the no‐EPA group and 153 ± 114 mg/dL in the EPA group (*P* = 0.803). Other characteristics including medications and concomitant diseases were similar in both groups. The type and doses of EPAs administered in 12 patients in the EPA group were as follows: ethyl icosapentate, 1800 mg/day (n = 5); ethyl icosapentate, 2700 mg/day (n = 1); and omega‐3‐acid ethyl esters, 2 g/day (n = 6).

###### 

Baseline patient characteristics

                                                        No‐EPA (n = 48)   EPA (n = 12)   *P* value
  ----------------------------------------------------- ----------------- -------------- -----------
  Age (years)                                           70.1 ± 9.2        71.3 ± 7.4     0.660
  Male                                                  37 (77)           10 (83)        0.638
  Body mass index                                       24.5 ± 3.9        23.9 ± 1.9     0.451
  Diabetes mellitus                                     18 (38)           7 (58)         0.190
  Hypertension                                          41 (85)           9 (75)         0.403
  Dyslipidemia                                          44 (92)           11 (92)        1.000
  Chronic kidney disease (no hemodialysis)              10 (21)           2 (17)         0.747
  Hemodialysis                                          6 (13)            1 (8)          0.688
  Sleep apnea syndrome                                  5 (10)            1 (8)          0.830
  Current smoker                                        3 (6)             1 (8)          0.796
  Family history of coronary artery disease             3 (6)             1 (8)          0.796
  History of PCI or CABG                                28 (58)           8 (67)         0.746
  History of myocardial infarction                      15 (31)           6 (50)         0.312
  History of TIA or cerebral infarction                 7 (15)            2 (17)         0.857
  History of peripheral artery disease                  3 (6)             1 (8)          0.796
  Prior statin use                                      35 (73)           9 (75)         0.884
  Prior aspirin use                                     31 (65)           10 (83)        0.306
  Prior clopidogrel use                                 22 (46)           9 (75)         0.071
  Prior ACEI or ARB use                                 21 (44)           5 (42)         0.896
  Prior calcium channel blocker use                     25 (52)           5 (42)         0.519
  Prior beta blocker use                                14 (29)           5 (42)         0.493
  Prior ezetimibe use                                   5 (10)            2 (17)         0.619
  Duration of prior EPA use                                                              
  Duration \<1 month                                                      0              ---
  1‐12 months                                                             9 (75)         ---
  ≥12 months                                                              3 (25)         ---
  Hemoglobin (g/dL)                                     13.2 ± 1.7        13.7 ± 1.5     0.416
  HbA1c (%)                                             6.2 ± 0.8         6.5 ± 0.8      0.255
  Glucose (mg/dL)                                       124 ± 36          125 ± 28       0.944
  LDL‐C (mg/dL)                                         94 ± 29           97 ± 36        0.807
  Triglyceride (mg/dL)                                  161 ± 92          153 ± 114      0.803
  HDL‐C (mg/dL)                                         47 ± 10           50 ± 7         0.345
  LDL‐C to HDL‐C ratio                                  2.2 ± 1.7         2.0 ± 0.9      0.628
  EPA/AA ratio[a](#clc23185-note-0003){ref-type="fn"}   0.48 ± 0.21       1.63 ± 0.46    \<0.001
  Ca (mg/dL)                                            9.2 ± 0.3         9.4 ± 0.5      0.165
  Acute coronary syndrome                               9 (19)            1 (8)          0.670
  ST‐segment elevation myocardial infarction            3 (6)             0              0.374
  Non‐ST‐segment elevation myocardial infarction        6 (13)            1 (8)          0.688

*Note*: Values are presented as mean ± SD or number (%) of observations.

Abbreviations: AA, arachidonic acid; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; EPA, eicosapentaenoic acid; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

n = 31 (10 in EPA group and 21 in no‐EPA group).

3.2. Angiographic findings {#clc23185-sec-0015}
--------------------------

Plaque location and angiographic data are shown in Table [2](#clc23185-tbl-0002){ref-type="table"}. Diameter stenosis was similar between the no‐EPA and EPA groups (85.9 ± 11.5 vs 86.4 ± 16.5, *P* = 0.885). No significant differences in plaque location and other angiographic data were observed between both groups.

###### 

Angiographic and procedural characteristics

                                   No‐EPA (n = 48)   EPA (n = 12)   *P* value
  -------------------------------- ----------------- -------------- -----------
  Plaque location                                                   
  LAD, n (%)                       31 (65)           4 (33)         0.102
  LCX, n (%)                       2 (4)             3 (25)         0.050
  RCA, n (%)                       15 (31)           5 (42)         0.511
  Minimum lesion diameter, mm      1.01 ± 0.56       0.96 ± 0.54    0.763
  Reference diameter, mm           3.02 ± 0.52       3.12 ± 0.50    0.578
  Lesion length, mm                19.7 ± 9.6        18.5 ± 9.0     0.691
  Diameter stenosis, %             85.9 ± 11.5       86.4 ± 16.5    0.885
  Pre‐dilatation, n (%)            11 (23)           3 (25)         0.879
  Aspiration thrombectomy, n (%)   3 (6)             0              0.374

Abbreviations: LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

3.3. Plaque characteristics assessed using OFDI {#clc23185-sec-0016}
-----------------------------------------------

The results of the qualitative and semiquantitative analysis of various coronary plaque characteristics using OFDI are compared in Table [3](#clc23185-tbl-0003){ref-type="table"}. The mean lipid index (818 ± 806 vs 1574 ± 891) and macrophage grade (13.5 ± 5.9 vs 19.3 ± 7.4) were significantly lower in the EPA group than in the no‐EPA group (*P* = 0.010 and *P* = 0.019, respectively). However, the mean minimum FCT (109.2 ± 55.7 μm vs 81.6 ± 36.4 μm) was higher in the EPA group than in the no‐EPA group (*P* = 0.040).

###### 

Characteristics assessed using optical frequency domain imaging

                                       No‐EPA (n = 48)   EPA (n = 12)   *P* value
  ------------------------------------ ----------------- -------------- -----------
  Plaque rupture                       5 (10)            1 (8)          0.830
  Plaque erosion                       4 (8)             1 (8)          1.000
  Luminal thrombus                     9 (19)            2 (17)         0.868
  Lipid‐rich plaque                    37 (77)           6 (50)         0.081
  Maximum lipid arc (degree)           236 ± 84          161 ± 106      0.011
  Lipid length (mm)                    6.2 ± 2.6         3.8 ± 2.8      0.007
  Lipid index                          1574 ± 891        818 ± 806      0.010
  Thin‐cap fibroatheroma               20 (42)           3 (25)         0.334
  Minimum fibrous cap thickness (μm)   81.6 ± 36.4       109.2 ± 55.7   0.040
  Macrophage infiltration              48 (100)          12 (100)       1.000
  Macrophage grade                     19.3 ± 7.4        13.5 ± 5.9     0.019
  Cholesterol crystals                 17 (35)           3 (25)         0.734
  Microchannels                        45 (94)           11 (92)        0.796
  Number of microchannels (/section)   0.37 ± 0.30       0.23 ± 0.26    0.063
  Calcification                        37 (77)           6 (50)         0.081
  Maximum thickness of calcification   637 ± 364         743 ± 374      0.510

3.4. Multiple logistic regression analyses for lipid index, TCFA, and macrophage invasion {#clc23185-sec-0017}
-----------------------------------------------------------------------------------------

Multiple logistic regression analyses were performed to assess the risk factors for lipid index, TCFA, and macrophage invasion (n = 60). Because LDL cholesterol to HDL cholesterol ratio was negatively correlated with HDL cholesterol concentration (*r* = −0.675, *P* \< 0.001), it was excluded from the multiple variable analysis. Triglyceride concentration and prior EPA use were not significantly correlated with HDL cholesterol concentration (*r* = −0.205, *P* = 0.117, and *r* = −0.033, *P* = 0.803, respectively). Prior EPA use and HDL cholesterol concentration were independently associated with lipid index (Table [4](#clc23185-tbl-0004){ref-type="table"}), whereas HDL cholesterol concentration was associated with TCFA (Table [5](#clc23185-tbl-0005){ref-type="table"}). Moreover, CKD and prior EPA use were associated with macrophage infiltration (Table [6](#clc23185-tbl-0006){ref-type="table"}).

###### 

Logistic regression analysis of lipid index

                                                   Analysis                                       
  ------------------------------------------------ ------------------- ------- ------------------ -------
  Age (years)                                      1.52 (0.50‐4.61)    0.460                      
  Male                                             1.33 (0.37‐4.77)    0.658                      
  Body mass index                                  6.33 (0.75‐53.5)    0.090                      
  Diabetes mellitus                                1.11 (0.37‐3.31)    0.853                      
  Hypertension                                     0.83 (0.19‐3.63)    0.807                      
  Dyslipidemia                                     1.37 (0.21‐8.94)    0.742                      
  Chronic kidney disease (no hemodialysis)         7.21 (0.86‐60.5)    0.069                      
  Hemodialysis                                     3.35 (0.38‐30.0)    0.279                      
  Sleep apnea syndrome                             0.46 (0.08‐2.52)    0.370                      
  Current smoker                                   0.15 (0.01‐1.50)    0.105                      
  Family history of coronary artery disease        1.54 (0.15‐15.8)    0.716                      
  History of PCI or CABG                           1.00 (0.33‐2.99)    1.000                      
  History of myocardial infarction                 1.40 (0.44‐4.43)    0.567                      
  History of TIA or cerebral infarction            0.57 (0.14‐2.42)    0.447                      
  History of peripheral artery disease             1.54 (0.15--15.8)   0.716                      
  Prior statin use                                 1.29 (0.39‐4.25)    0.680                      
  Prior aspirin use                                0.89 (0.28‐2.85)    0.844                      
  Prior clopidogrel use                            1.11 (0.38‐3.24)    0.855                      
  Prior ACEI or ARB use                            0.67 (0.23‐1.97)    0.462                      
  Prior calcium channel blocker use                1.35 (0.46‐3.97)    0.584                      
  Prior beta blocker use                           0.57 (0.18‐1.77)    0.329                      
  Prior eicosapentaenoic acid use                  0.27 (0.07‐0.99)    0.048   0.19 (0.04‐0.95)   0.043
  Prior ezetimibe use                              3.35 (0.38--30.0)   0.279                      
  Hemoglobin (g/dL)                                0.44 (0.15‐1.34)    0.148                      
  HbA1c (%)                                        2.25 (0.43‐11.8)    0.336                      
  Glucose (mg/dL)                                  2.15 (0.60‐7.70)    0.238                      
  LDL‐C (mg/dL)                                    2.79 (0.91‐8.50)    0.072                      
  Triglyceride (mg/dL)                             5.67 (1.65‐19.5)    0.006   3.71 (0.87‐15.8)   0.077
  HDL‐C (mg/dL)                                    0.16 (0.05‐0.51)    0.002   0.19 (0.05‐0.73)   0.016
  LDL‐C to HDL‐C ratio                             4.50 (1.43‐14.2)    0.010                      
  Ca (mg/dL)                                       4.67 (1.28‐17.0)    0.020   4.04 (0.83‐19.7)   0.084
  Acute coronary syndrome                          1.20 (0.28‐5.25)    0.807                      
  ST‐segment elevation myocardial infarction       1.00 (0.09‐11.7)    1.000                      
  Non‐ST‐segment elevation myocardial infarction   0.63 (0.13‐3.13)    0.572                      

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CI, confidence interval; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; OR, odds ratio; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

###### 

Logistic regression analysis of thin‐cap fibroatheroma

                                                   Analysis                                       
  ------------------------------------------------ ------------------- ------- ------------------ -------
  Age (years)                                      2.26 (0.65‐7.86)    0.200                      
  Male                                             2.47 (0.60‐10.1)    0.210                      
  Body mass index                                  0.34 (0.09‐1.39)    0.133                      
  Diabetes mellitus                                1.51 (0.53‐4.32)    0.446                      
  Hypertension                                     0.56 (0.14‐2.21)    0.410                      
  Dyslipidemia                                     0.93 (0.14‐6.01)    0.936                      
  Chronic kidney disease (no hemodialysis)         4.40 (1.15‐16.9)    0.031   4.10 (0.90‐18.7)   0.068
  Hemodialysis                                     2.39 (0.48‐11.8)    0.286                      
  Sleep apnea syndrome                             0.29 (0.03‐2.66)    0.274                      
  Current smoker                                   0.52 (0.05‐5.27)    0.576                      
  Family history of coronary artery disease        1.67 (0.22‐12.7)    0.622                      
  History of PCI or CABG                           1.43 (0.49‐4.19)    0.516                      
  History of myocardial infarction                 3.39 (1.12‐10.3)    0.031   3.30 (0.94‐11.6)   0.062
  History of TIA or cerebral infarction            0.41 (0.08‐2.16)    0.292                      
  History of peripheral artery disease             5.40 (0.53‐55.4)    0.156                      
  Prior statin use                                 0.52 (0.16‐1.65)    0.266                      
  Prior aspirin use                                1.10 (0.36‐3.38)    0.872                      
  Prior clopidogrel use                            0.78 (0.28‐2.21)    0.639                      
  Prior ACEI or ARB use                            1.34 (0.47‐3.84)    0.580                      
  Prior calcium channel blocker use                0.65 (0.23‐1.86)    0.427                      
  Prior beta blocker use                           0.46 (0.14‐1.50)    0.197                      
  Prior eicosapentaenoic acid use                  0.47 (0.11‐1.94)    0.295                      
  Prior ezetimibe use                              2.39 (0.48--11.8)   0.286                      
  Hemoglobin (g/dL)                                3.20 (0.79‐12.9)    0.102                      
  HbA1c (%)                                        1.69 (0.59‐4.89)    0.331                      
  Glucose (mg/dL)                                  2.58 (0.88‐7.59)    0.086                      
  LDL‐C (mg/dL)                                    1.83 (0.64‐5.27)    0.263                      
  Triglyceride (mg/dL)                             2.41 (0.78‐7.48)    0.128                      
  HDL‐C (mg/dL)                                    0.14 (0.04‐0.56)    0.005   0.19 (0.05‐0.81)   0.024
  LDL‐C to HDL‐C ratio                             2.79 (0.90‐8.69)    0.077                      
  Ca (mg/dL)                                       2.82 (0.69‐11.5)    0.148                      
  Acute coronary syndrome                          0.64 (0.15‐2.79)    0.555                      
  ST‐segment elevation myocardial infarction       3.43 (0.29‐40.1)    0.326                      
  Non‐ST‐segment elevation myocardial infarction   0.24 (0.03‐2.09)    0.194                      

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CI, confidence interval; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; OR, odds ratio; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

###### 

Logistic regression analysis of macrophage accumulation

                                                   Analysis                                       
  ------------------------------------------------ ------------------- ------- ------------------ -------
  Age (years)                                      3.78 (0.70‐20.5)    0.123                      
  Male                                             1.67 (0.48‐5.86)    0.424                      
  Body mass index                                  3.56 (0.84‐15.0)    0.085                      
  Diabetes mellitus                                1.29 (0.46‐3.60)    0.631                      
  Hypertension                                     0.92 (0.24‐3.60)    0.908                      
  Dyslipidemia                                     1.45 (0.22‐9.34)    0.698                      
  Chronic kidney disease (no hemodialysis)         7.63 (1.50‐38.7)    0.014   9.71 (1.57‐60.1)   0.014
  Hemodialysis                                     1.49 (0.30‐7.33)    0.621                      
  Sleep apnea syndrome                             1.08 (0.20‐5.82)    0.931                      
  Current smoker                                   0.33 (0.03‐3.40)    0.354                      
  Family history of coronary artery disease        1.07 (0.14‐8.17)    0.945                      
  History of PCI or CABG                           0.90 (0.32‐2.52)    0.833                      
  History of myocardial infarction                 2.34 (0.79‐6.93)    0.126                      
  History of TIA or cerebral infarction            0.25 (0.05‐1.34)    0.107                      
  Prior statin use                                 0.91 (0.29‐2.87)    0.876                      
  Prior aspirin use                                0.57 (0.19‐1.71)    0.315                      
  Prior clopidogrel use                            1.00 (0.37‐2.77)    0.993                      
  Prior ACEI or ARB use                            1.13 (0.41‐3.13)    0.821                      
  Prior calcium channel blocker use                1.14 (0.42‐3.15)    0.796                      
  Prior beta blocker use                           1.29 (0.43‐3.83)    0.650                      
  Prior eicosapentaenoic acid use                  0.16 (0.03‐0.79)    0.025   0.12 (0.02‐0.76)   0.024
  Prior ezetimibe use                              1.49 (0.30--7.33)   0.621                      
  Hemoglobin (g/dL)                                1.57 (0.48‐5.14)    0.458                      
  HbA1c (%)                                        1.96 (0.69‐5.59)    0.208                      
  Glucose (mg/dL)                                  2.24 (0.79‐6.32)    0.128                      
  LDL‐C (mg/dL)                                    2.19 (0.68‐7.10)    0.190                      
  Triglyceride (mg/dL)                             2.63 (0.92‐7.49)    0.070                      
  HDL‐C (mg/dL)                                    2.95 (0.98‐8.89)    0.055                      
  LDL‐C to HDL‐C ratio                             2.94 (0.92‐9.36)    0.068                      
  Ca (mg/dL)                                       2.98 (0.81‐10.9)    0.099                      
  Acute coronary syndrome                          1.08 (0.28‐4.21)    0.908                      
  ST‐segment elevation myocardial infarction       2.22 (0.19‐25.9)    0.524                      
  Non‐ST‐segment elevation myocardial infarction   0.78 (0.16‐3.82)    0.758                      

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CI, confidence interval; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; OR, odds ratio; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

3.5. Correlations of lipid index, TCFA, and microchannels with macrophage grade {#clc23185-sec-0018}
-------------------------------------------------------------------------------

Significant correlations were observed between lipid index, FCT, and macrophage grade. Lipid index was positively correlated with macrophage grade (*r* = 0.803, *P* \< 0.001; Figure S2). In contrast, minimum FCT was negatively correlated with macrophage grade (*r* = −0.650, *P* \< 0.001; Figure S3). The correlation between macrophage grade and the number of microchannels was not statistically significant (*r* = 0.096, *P* = 0.467). However, in 31 patients in whom the maximum lipid arc was \<270°, a weak but positive correlation between macrophage grade and the number of microchannels was observed (*r* = 0.421, *P* = 0.018; Figure S4).

3.6. Observer variabilities {#clc23185-sec-0019}
---------------------------

Images obtained using OFDI were analyzed by two independent observers. The inter‐observer reliabilities and intra‐observer reproducibilities measured by Pearson\'s coefficient were *r* = 0.90 and 0.93 for lipid index, *r* = 0.90 and 0.94 for minimum FCT, *r* = 0.89 and 0.92 for macrophage grade, and *r* = 0.92 and 0.95 for the number of microchannels, respectively.

4. DISCUSSION {#clc23185-sec-0020}
=============

In the present study, the following main observations were of note: First, patients who received EPA therapy had lower lipid burden, higher FCT, and less macrophage accumulation than those who did not receive EPA therapy. Second, in patients undergoing PCI, prior EPA use and HDL cholesterol concentration were independent predictors of lipid index, HDL cholesterol concentration was an independent predictor of TCFA, whereas CKD and prior EPA use were independent predictors of macrophage grade. To the best of our knowledge, this study is the first in‐depth comparison of coronary artery plaques in patients who received and did not receive EPA therapy using propensity score matching and the first analysis of correlations among the characteristics of unstable plaques in patients who underwent PCI using OFDI. These observations further our understanding of the pharmacological effect of EPA therapy, which may have important implications with respect to the management of patients presenting with CAD.

This study suggests that EPA therapy itself is effective for coronary plaque stabilization. As shown in Table [3](#clc23185-tbl-0003){ref-type="table"}, we observed that patients who received EPA therapy had lower lipid burden, higher FCT, and less macrophage accumulation than those who did not receive EPA therapy (*P* = 0.010, 0.040, 0.019, respectively). Nonetheless, patient background (including mean LDL cholesterol and triglyceride concentrations), except for EPA/arachidonic acid ratio, was not statistically different between the two groups (*P* = 0.803, Table [1](#clc23185-tbl-0001){ref-type="table"}). Watanabe et al. showed that lipid volume and plaque volume reductions with EPA therapy were independent of decreases in LDL cholesterol and triglyceride concentrations,[17](#clc23185-bib-0017){ref-type="ref"} which is consistent with our results.

4.1. Lipid‐rich plaque {#clc23185-sec-0021}
----------------------

An important mechanism of plaque rupture is a large lipid core, which mechanically enhances the tension of fibrous cap covering the lipid core, resulting in plaque disruption.[25](#clc23185-bib-0025){ref-type="ref"} EPA therapy might reduce lipid core size by inhibiting macrophage accumulation. Wu et al showed that EPA therapy reduced the level of oxidized LDL‐induced cell apoptosis, preventing atherosclerotic progression.[26](#clc23185-bib-0026){ref-type="ref"} Ferguson et al. reported that EPA attenuated the inflammatory activation of in vitro human adipocytes and reduced lipogenesis.[27](#clc23185-bib-0027){ref-type="ref"} In the process of atherosclerotic development, lipid‐core enlargement is accelerated by apoptotic macrophage accumulation and elevated chemokine expression followed by intimal recruitment of circulating monocytes.[28](#clc23185-bib-0028){ref-type="ref"} In the present study, macrophage grade was significantly lower in the EPA group than in the no‐EPA group (Table [3](#clc23185-tbl-0003){ref-type="table"}) and was positively correlated with lipid index (Figure S2). Therefore, less macrophage accumulation might contribute to decreased lipid core in the EPA group.

4.2. FCT {#clc23185-sec-0022}
--------

TCFA is one of the most important characteristics of unstable plaques in the coronary and carotid arteries.[29](#clc23185-bib-0029){ref-type="ref"}, [30](#clc23185-bib-0030){ref-type="ref"} Several mechanisms could elucidate the higher FCT in the EPA group than in the no‐EPA group. First, EPA therapy inhibits the ability of macrophages to secrete matrix metalloproteinase (MMP) and monocyte chemotactic protein (MCP)‐1.[31](#clc23185-bib-0031){ref-type="ref"} As shown in Figure S3, minimum FCT was inversely correlated with macrophage grade. Because the MMPs released by macrophages induce the thinning of fibrous caps of atherosclerotic plaques via collagen breakdown,[32](#clc23185-bib-0032){ref-type="ref"} less macrophage accumulation in the plaque might contribute to the higher FCT in the EPA group (Table [3](#clc23185-tbl-0003){ref-type="table"}). Second, EPA lowered the levels of pentraxin 3, an inflammatory marker associated with TCFA.[33](#clc23185-bib-0033){ref-type="ref"}, [34](#clc23185-bib-0034){ref-type="ref"} Yamano et al. showed that EPA administration for 8 months significantly increased the FCT in OCT analysis for non‐culprit plaques with a percent diameter stenosis of 30% to 70%.[35](#clc23185-bib-0035){ref-type="ref"} Although the mean minimum FCT was higher in the EPA group than in the no‐EPA group (Table [3](#clc23185-tbl-0003){ref-type="table"}), EPA therapy was not an independent predictor of TCFA, probably because of the small sample size (Table [5](#clc23185-tbl-0005){ref-type="table"}).

4.3. Macrophage accumulation {#clc23185-sec-0023}
----------------------------

There are several mechanisms for reduced macrophage accumulation by EPA. First, EPA is incorporated into atherosclerotic plaques, and a higher EPA content in the plaques is associated with a reduced number of foam cells and T cells and less inflammation, leading to increased stability.[36](#clc23185-bib-0036){ref-type="ref"} Second, Yamada et al reported that EPA acts as an anti‐inflammatory agent that reduces the production of pro‐inflammatory eicosanoid mediators from arachidonic acid and decreases adhesion molecule expression.[37](#clc23185-bib-0037){ref-type="ref"} Furthermore, they showed the in vivo and in vitro inhibition of monocyte adhesion to aortic endothelial cells by EPA. Third, monocyte recruitment into atherosclerotic plaques is also reduced by EPA via favorable alteration of monocyte subsets independent of effects on plasma cholesterol.[38](#clc23185-bib-0038){ref-type="ref"} Fourth, macrophages extravasating from intraplaque microvessels might be inhibited by EPA via reduction in vascular endothelial growth factor and Flk‐1 receptor expression.[39](#clc23185-bib-0039){ref-type="ref"}, [40](#clc23185-bib-0040){ref-type="ref"} In the present study, the mean number of microchannels was lower in the EPA group than in the no‐EPA group, albeit without statistically significant difference (Table [3](#clc23185-tbl-0003){ref-type="table"}). These mechanisms might explain the association between EPA therapy and lower macrophage grade.

4.4. Other observations {#clc23185-sec-0024}
-----------------------

Prior statin use was not significantly associated with plaque stability in the current study (Tables [4](#clc23185-tbl-0004){ref-type="table"}, [5](#clc23185-tbl-0005){ref-type="table"}, [6](#clc23185-tbl-0006){ref-type="table"}). JCAD study showed that if three or more major coronary risk factors are present, the risk for cardiovascular events is 1.3‐fold higher compared to having two or fewer risk factors.[41](#clc23185-bib-0041){ref-type="ref"} In this study, 35 patients (58%) had three or more major coronary risk factors, which means that the prevalence of high‐risk patients was considerably high. Although such high‐risk patients should have more intensive LDL cholesterol‐lowering therapy,[42](#clc23185-bib-0042){ref-type="ref"} the mean LDL cholesterol concentration was 94.6 mg/dL in this study. Therefore, prior statin use might not be a statistically significant factor due to inadequate LDL cholesterol‐lowering therapy, or small sample size.

4.5. EPA therapy for patients with unstable plaques: clinical perspectives {#clc23185-sec-0025}
--------------------------------------------------------------------------

Several intravascular ultrasound or computed tomography studies have shown that EPA therapy attenuates plaque instability.[15](#clc23185-bib-0015){ref-type="ref"}, [16](#clc23185-bib-0016){ref-type="ref"}, [17](#clc23185-bib-0017){ref-type="ref"}, [18](#clc23185-bib-0018){ref-type="ref"} In the present study, multiple regression analyses indicated that previous EPA administration was one of the independent predictors of the characteristics of unstable plaques (Tables [4](#clc23185-tbl-0004){ref-type="table"}, [5](#clc23185-tbl-0005){ref-type="table"}, [6](#clc23185-tbl-0006){ref-type="table"}). The results of this study support the hypothesis that EPA therapy is associated with decreased plaque instability. There exists evidence that EPA therapy improves endothelial function[43](#clc23185-bib-0043){ref-type="ref"} and reduces the risk of cardiovascular events.[2](#clc23185-bib-0002){ref-type="ref"} The recently published Reduction of Cardiovascular Events With Icosapent Ethyl--Intervention Trial showed a 25% reduction in primary composite endpoints (coronary revascularization or unstable angina) and a 26% reduction in secondary endpoints (cardiovascular death, myocardial infarction, and stroke).[3](#clc23185-bib-0003){ref-type="ref"}, [44](#clc23185-bib-0044){ref-type="ref"} Therefore, besides stringent management of other coronary risk factors, EPA therapy might be effective for the secondary prevention of adverse cardiovascular events and the stabilization of unstable plaques in patients with CAD.

4.6. Study limitations {#clc23185-sec-0026}
----------------------

The present study has some limitations. First, this retrospective, cross‐sectional study had a small sample size and was conducted at a single medical center within Japan, where people generally have a higher omega‐3 dietary intake in comparison to many other countries. Its results need to be confirmed by a study that enrolls a larger number of patients. Second, there is an inherent discrepancy between characteristics assessed using OFDI and real histopathological findings, as shown in a previous comparison study.[45](#clc23185-bib-0045){ref-type="ref"} For example, this study could not fully evaluate the presence of intraplaque microchannels, one of the important features of vulnerable plaques, because the near‐infrared light irradiating from the OFDI catheter cannot penetrate through a lipid‐rich plaque and cannot visualize microchannels outside a lipid‐rich plaque. Therefore, further analyses using OFDI with higher resolution and penetration might enable more detailed assessment of intraplaque microstructures in patients undergoing PCI. Third, we do not have additional information on biochemical markers, including pentraxin 3, MMP, MCP‐1, and high‐sensitivity C‐reactive protein. Fourth, the type of drugs, dosing regimen, and duration of therapy were different in EPA group.

5. CONCLUSIONS {#clc23185-sec-0027}
==============

This OFDI analysis suggests that EPA therapy is associated with decreased plaque instability in patients with CAD undergoing PCI. Patients with CAD who are at high risk for cardiovascular events should receive EPA therapy as intensive medical management for the stabilization of coronary atherosclerotic plaques.
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**Figure S1.** Semiquantification of macrophage accumulation by optical frequency domain imaging (OFDI). Representative cross‐sectional images of macrophage accumulation obtained using OFDI with the following grades: A, grade 0, no macrophage; B, grade 1, localized accumulation; C, grade 2, clustered accumulation in \<1 quadrant; D, grade 3, clustered accumulation in ≥1 quadrant and \<3 quadrants; and E, grade 4, clustered accumulation in ≥3 quadrants.

###### 

Click here for additional data file.

###### 

**Figure S2.** Correlation between lipid index and macrophage grade. Lipid index was positively correlated with macrophage grade (*r* = 0.803, *P* \< 0.001).
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Click here for additional data file.

###### 

**Figure S3.** Correlation between minimum FCT and macrophage grade

FCT was negatively correlated with macrophage grade (*r* = −0.650, *P* \< 0.001).

###### 

Click here for additional data file.

###### 

**Figure S4** Correlation between the number of microchannels and macrophage grade. The number of microchannels was weakly but positively correlated with macrophage grade (*r* = 0.421, *P* = 0.018; n = 31\*). \*These 31 patients had a maximum lipid arc of \<270°.
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Click here for additional data file.
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